In preclinical models of various cancer types, loss of PTEN leads to the accumulation of immunoregulatory cells—including MDSCs, Tregs, and M2-polarized macrophages—which collectively inhibit cytotoxic immune activity [70]. This evidence concerns the gene PTEN and cancer.